US2023076630A1PendingUtilityA1

Mesenchymal stem cells and uses therefor

84
Assignee: MESOBLAST INT SARLPriority: Mar 22, 2004Filed: Jun 9, 2022Published: Mar 9, 2023
Est. expiryMar 22, 2024(expired)· nominal 20-yr term from priority
Inventors:Sudeepta AggarwalMark F. PittengerTimothy Varney
A61P 37/06C12N 5/0664C12N 5/0662A61P 37/08C12N 5/0663A61P 17/06A61P 1/02A61K 38/2026A61K 38/2066A61P 27/02C12N 5/0667A61P 13/08A61K 35/28A61P 1/00A61P 3/10C12N 5/0665A61P 7/06A61P 17/00A61P 17/14C12N 5/0668A61K 2035/124A61P 7/04A61P 11/00A61P 35/00A61P 5/14Y02A50/30A61K 35/12C12N 5/0666A61P 17/02A61P 43/00A61P 25/00A61P 9/00A61P 19/02A61P 29/00A61P 19/08A61P 37/00A61K 45/06A61P 37/02A61P 1/04
84
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Claims

exact text as granted — not AI-modified
1 .- 20 . (canceled) 
     
     
         21 . A method for reducing or limiting inflammation in a human comprising administering genetically unmanipulated mesenchymal stem cells to the human, wherein the administration mediates a shift in the T cell population in the human from pro-inflammatory TH1 cells to anti-inflammatory TH2 cells. 
     
     
         22 . The method of  claim 21 , wherein the inflammation is in the brain or gut. 
     
     
         23 . The method of  claim 21 , wherein the human has inflammatory bowel disease. 
     
     
         24 . The method of  claim 21 , wherein the human has an inflammatory bowel disease, and the mesenchymal stem cells promote increased secretion of interleukin 10. 
     
     
         25 . The method of  claim 21 , wherein the human has an inflammatory bowel disease, and the mesenchymal stem cells promote generation of T reg  cells. 
     
     
         26 . The method of  claim 21 , wherein the mesenchymal stem cells are allogeneic. 
     
     
         27 . The method of  claim 21 , wherein the mesenchymal stem cells are autologous. 
     
     
         28 . The method of  claim 21 , wherein the mesenchymal stem cells are administered by intravenous, intraarterial, or intraperitoneal administration. 
     
     
         29 . The method of  claim 21 , wherein the mesenchymal stem cells are administered as a cell suspension in a pharmaceutically acceptable liquid medium. 
     
     
         30 . The method of  claim 21 , wherein the mesenchymal stem cells were harvested from a mesenchymal stem cell containing tissue, isolated, and expanded in culture. 
     
     
         31 . The method of  claim 23 , wherein the mesenchymal stem cells are allogeneic. 
     
     
         32 . The method of  claim 23 , wherein the mesenchymal stem cells are autologous. 
     
     
         33 . The method of  claim 23 , wherein the mesenchymal stem cells are administered by intravenous, intraarterial, or intraperitoneal administration. 
     
     
         34 . The method of  claim 23 , wherein the mesenchymal stem cells are administered as a cell suspension in a pharmaceutically acceptable liquid medium. 
     
     
         35 . The method of  claim 23 , wherein the mesenchymal stem cells were harvested from a mesenchymal stem cell containing tissue, isolated, and expanded in culture. 
     
     
         36 . The method of  claim 24 , wherein the mesenchymal stem cells are allogeneic. 
     
     
         37 . The method of  claim 24 , wherein the mesenchymal stem cells are autologous. 
     
     
         38 . The method of  claim 24 , wherein the mesenchymal stem cells are administered by intravenous, intraarterial, or intraperitoneal administration. 
     
     
         39 . The method of  claim 25 , wherein the mesenchymal stem cells are allogeneic. 
     
     
         40 . The method of  claim 25 , wherein the mesenchymal stem cells are autologous.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.